Table 1.
Participant timeline in REGATTA
| Activity | Patient Contact | Baseline | Follow-up | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 28 | |
| Visit Number | I | II | ||||||||
| Screening | X | |||||||||
| Informed Consent | X | |||||||||
| Inclusion / Exclusion criteria | X | |||||||||
| Medical History, Examination | X | |||||||||
| Urine Testsa | X | |||||||||
| Pregnancy Test | X | |||||||||
| Drug Intakeb | X | X | X | X | X | X | ||||
| Symptom Assessment and Activity Impairment (Diary) | X | X | X | X | X | X | X | X | ||
| Additional Antibiotic Courses | X | X | X | X | X | X | X | X | ||
| Painkiller Intake | X | X | X | X | X | X | X | X | ||
| Adverse Events and Complications | X | X | X | X | X | X | X | X | ||
| Recurrent UTI (Questionnaire) | X | |||||||||
| Return of Drug Packages | X | |||||||||
| Phone Calls to Remind Patients (Diary, Drug Return, Questionnaire) | X | X | X | |||||||
aMidstream urine for on-site dipstick test (leukocytes, nitrite, red blood cells) and for urine culture (pathogens and resistances)
bDrug intake until all 30 tablets are finished (= 3 × 2 tablets uva-ursi daily for 5 days)